U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Ditch the painkillers! While they can provide temporary relief, there are other ways to numb pain without medication. Find ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they remain underutilised, says Rong Xu, PhD, professor at Case Western Reserve ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making ...